NEW
The ImmunAID clinical study has been approved by the French ethical committee (CPP) we expect to open centers in France May and recruit the first patients in June.
ImmunAID is a large scale translational research project whose objective is to optimize the diagnostic, classification and clinical management of patients with auto–inflammatory disorders (AID). Indeed, there is a dramatic unmet need in several rare disorders characterized by huge clinical and biological inflammation, for which no robust and validated classification criteria have been established. The project focuses on rare sporadic AID of unknown pathogenesis and will enable the constitution of homogeneous groups of patients, through European existing cohorts of patients
The ImmunAID clinical study has been approved by the French ethical committee (CPP) we expect to open centers in France May and recruit the first patients in June.
Total Cost
15.8 M€
Partnership
24
EU contribution
15.8 M€
Partner countries
12
Grant agreement no: 779295
Funded under: H2020-EU.3.1.1.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779295
INSERM
Institut National de la Santé et de la Recherche Médicale